Regulation of dendritic cell function and tumor immunity by TIM-3
Regulation of dendritic cell function and tumor immunity by TIM-3
批准号:
10018832
负责人:
Brian Ruffell
金额:
$39.35万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-16 至 2024-08-31
关键词:
AntibodiesAntigensAntitumor ResponseBreast Cancer ModelBreast Cancer PatientBreast CarcinomaCD8-Positive T-LymphocytesCXCL9 geneCXCR3 geneCell CommunicationCell physiologyCessation of lifeCombination immunotherapyCombined Modality TherapyCytotoxic T-LymphocytesDNADendritic CellsDendritic cell activationDendritic cell tumorDiagnosisDigestionDiseaseEnvironmentGene Expression ProfilingGoalsGranzymeIFNAR1 geneImmuneImmunoglobulinsImmunotherapyIn VitroInterferonsLigandsMalignant NeoplasmsMammary NeoplasmsMediatingModelingMolecularMucinsMusMutationMyelogenousNucleic AcidsPD-1/PD-L1PD-L1 blockadePaclitaxelPathway interactionsPatientsPeripheralPlayPopulationProcessPublishingRefractoryRegulationRegulatory PathwayRoleStimulator of Interferon GenesSurvival RateSystemT cell responseT-LymphocyteTherapeutic InterventionTissuesToll-like receptorsTransgenic ModelTumor AntigensTumor ImmunityTumor-infiltrating immune cellsUp-RegulationVirus DiseasesWomanadaptive immune responseanti-PD-1anti-PD-L1anti-tumor immune responsebasechemokinechemotherapycombinatorialcytotoxicdesigndraining lymph nodeexhaustexhaustionimmune checkpoint blockadeimprovedin vivolymph nodesmalignant breast neoplasmmolecular subtypesmouse modelneoplastic cellnovel strategiesphase 3 studypreventprogrammed cell death ligand 1responsesensorstandard of caretargeted treatmenttumortumor growthtumor microenvironmenttumor-immune system interactionstype I interferon receptor
中文摘要
项目总结
TIM-3对树突状细胞功能和肿瘤免疫的调节作用
肿瘤免疫依赖于抗原特异性细胞毒T细胞的从头激活和扩增
淋巴细胞。然而,为了影响肿瘤生长,这些T细胞也必须渗透到肿瘤中,克服
抑制环境,避免在存在持久性抗原的情况下筋疲力尽,这些障碍
被认为是免疫治疗的主要障碍。传统的树突状细胞被很好地建立为
适应性免疫反应的中心诱导者,但新出现的证据表明,它们也可能起到作用
支持包括肿瘤在内的周围组织中的T细胞活动。为了支持这一点,我们发现蒂姆-
3(T细胞免疫球蛋白和粘蛋白结构域包含-3)由肿瘤树突状细胞高表达,并且
TIM-3阻断体内外诱导趋化因子CXCL9的表达,从而促进T细胞
细胞毒效应在乳腺癌模型中的作用。在这里,我们建议鉴定树突状细胞
TIM-3改变的激活通路决定非迁移性树突状细胞是否维持T细胞功能
并确定树突状细胞表达CXCL9在肿瘤免疫中的作用。这些研究将
描绘一条可能的树突状细胞调控途径,提高我们对树突状细胞的作用的理解
肿瘤内的细胞,这两个因素可能对组合方案的设计具有重要意义
免疫疗法。
英文摘要
PROJECT SUMMARY
Regulation of dendritic cell function and tumor immunity by TIM-3
Tumor immunity is predicated upon the de novo activation and expansion of antigen-specific cytotoxic T
lymphocytes. However, to impact tumor growth these T cells must also infiltrate into tumors, overcome a
suppressive environment, and avoid becoming exhausted in the presence of persistent antigen, barriers that
are thought to be major impediments to immunotherapy. Conventional dendritic cells are well established as
the central inducers of the adaptive immune response, but emerging evidence suggests they may also play in
supporting T cell activity within peripheral tissues, including tumors. In support of this, we have found that TIM-
3 (T-cell immunoglobulin and mucin domain containing-3) is highly expressed by tumor dendritic cells, and that
TIM-3 blockade induces expression of the chemokine CXCL9 in vitro and in vivo, thereby promoting T cell
cytotoxic effector function in models of mammary carcinoma. Here we propose to identify the dendritic cell
activation pathways altered by TIM-3, determine if non-migratory dendritic cells maintain T cell function within
tumors, and determine the role of CXCL9 expression by dendritic cells in tumor immunity. These studies will
delineate a putative dendritic cell regulatory pathway and improve our understanding of the role of dendritic
cells within tumors, both factors that may have important implications for the design of combinatorial
immunotherapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of dendritic cell function and tumor immunity by TIM-3
-
批准号:10218098
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2019
-
负责人:Brian Ruffell
-
依托单位:
Regulation of dendritic cell function and tumor immunity by TIM-3
-
批准号:10475053
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2019
-
负责人:Brian Ruffell
-
依托单位:
Regulation of dendritic cell function and tumor immunity by TIM-3
-
批准号:10676810
-
项目类别:
-
资助金额:$38.56万
-
财政年份:2019
-
负责人:Brian Ruffell
-
依托单位:
Regulating Intratumoral Leukocytes to Improve Response to Chemotherapy
-
批准号:9031228
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2015
-
负责人:Brian Ruffell
-
依托单位:
Regulating Intratumoral Leukocytes to Improve Response to Chemotherapy
-
批准号:8790105
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2014
-
负责人:Brian Ruffell
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: